codiak-biosciences
(2)
Suchul Jang
He spent a decade engineering tiny vesicles to smuggle drugs where they were needed. Now he is running the American arm of a Korean biotech that wants the brain to clean up after itself - quietly, without the inflammation that has shadowed Alzheimer's drugs for years.
Phillip Maderia
Phillip Maderia is the Chief Executive Officer of PranaX, a Houston-based regenerative-medicine biotech developing stem cell-derived exosome products at the Levit Green campus in the Texas Medical Center. He joined in March 2025 after four years running Lonza's exosome manufacturing site in Lexington, Massachusetts - the facility Lonza bought from Codiak BioSciences in 2021, where Maderia had previously served as VP of Manufacturing Operations. He is a career biomanufacturing operator with roots at Sanofi Genzyme and LFB-USA and roughly three decades of scale-up experience.